Stockscreener 앱 받기
3.91
15.00%
-0.69
시간 외 거래:
4.00
0.09
+2.30%
전일 마감가:
$4.60
열려 있는:
$4.58
하루 거래량:
89,753
Relative Volume:
1.35
시가총액:
$101.53M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-23.03%
1개월 성능:
-63.04%
6개월 성능:
-65.40%
1년 성능:
+0.00%
1일 변동 폭
$3.90
$4.63
1주일 범위
$3.90
$5.325
52주 변동 폭
$3.90
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
명칭
Artiva Biotherapeutics Inc
전화
(858) 267-4467
주소
5505 MOREHOUSE DRIVE, SAN DIEGO
ARTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
3.91 | 101.53M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 개시 | Jefferies | Buy |
| 2024-08-13 | 개시 | Needham | Buy |
| 2024-08-13 | 개시 | TD Cowen | Buy |
| 2024-08-13 | 개시 | Wedbush | Outperform |
모두보기
Artiva Biotherapeutics Inc 주식(ARTV)의 최신 뉴스
Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm - In Vivo
JPMorgan Chase & Co. Buys New Holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics appoints new director and committee members - Investing.com India
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - GlobeNewswire
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Natural killer cells, a rising alternative to CAR-T cell therapy - Yahoo Finance
Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $21.00 - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Predicts ARTV FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2025 Earnings - MarketBeat
Barclays PLC Buys Shares of 19,616 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics surges on trading debut - MSN
Artiva Biotherapeutics announces pricing of upsized $167M IPO - MSN
Aligos Therapeutics (NASDAQ:ALGS) & Artiva Biotherapeutics (NASDAQ:ARTV) Head to Head Contrast - Defense World
Artiva Biotherapeutics, Inc.'s Lock-Up Period To End on January 15th (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics, Inc.’s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV) - Defense World
Geode Capital Management LLC Acquires Shares of 308,930 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Geode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Barclays PLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
State Street Corp Invests $1.34 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
State Street Corp Acquires Shares of 86,559 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
What is HC Wainwright’s Estimate for ARTV FY2024 Earnings? - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Average PT from Brokerages - Defense World
Research Analysts Issue Forecasts for ARTV FY2024 Earnings - MarketBeat
HC Wainwright & Co. Initiates Coverage of Artiva Biotherapeutics (ARTV) with Buy Recommendation - MSN
Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for growth - Investing.com India
Artiva Biotherapeutics’s SWOT analysis: NK cell therapy stock poised for growth - Investing.com Nigeria
Artiva Biotherapeutics (NASDAQ:ARTV) Now Covered by HC Wainwright - MarketBeat
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Franklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA - openPR
BNP Paribas Financial Markets Invests $42,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Charles Schwab Investment Management Inc. Invests $623,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Wellington Management Group LLP Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for autoimmune breakthrough - Investing.com India
After Making the IPO Jump, Biotechs Landed On a Slippery Slope - BioSpace
RA Capital Management L.P. Purchases Shares of 9,853,302 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
291,666 Shares in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Purchased by Samsara BioCapital LLC - MarketBeat
RTW Investments LP Invests $2.30 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Acuta Capital Partners LLC Purchases Shares of 44,000 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics Inc (ARTV) 재무 분석
Artiva Biotherapeutics Inc (ARTV)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Artiva Biotherapeutics Inc 주식 (ARTV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| 5AM Partners VI, LLC | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
833,333 |
9,999,996 |
1,182,054 |
| venBio Global Strategic Fund I | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,936,637 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
1,666,666 |
19,999,992 |
3,306,900 |
| GC Corp. | 10% Owner |
Jul 22 '24 |
Buy |
12.00 |
416,666 |
4,999,992 |
1,260,512 |
| Huh Yong-Jun | Director |
Jul 22 '24 |
Buy |
12.00 |
2,083,332 |
24,999,984 |
3,306,900 |
1.03%
자본화:
|
볼륨(24시간):